News

News

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.

Read more

Fighting cancer at an early stage

Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.

Read more

PHI´s new software available for customer delivery

In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.

Read more

PHI and BioSpherix sign co-marketing agreement

Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.

Read more

Biostock interview with CEO Peter Egelberg

Interview with CEO Peter Egelberg (Swedish) on biostock.se where he talks about PHI’s progress, where PHI is right now and where PHI wants to be in the near future. “Our goal is to be top of mind when researchers and scientists worldwide are looking for a new cell analytic tool”. You find the interview here.

Read more

New CEO commentary — “Redefining aging with HoloMonitor”

In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.

Read more

PHI at the Nordic Microscopy Society meeting, June 25-28

The Nordic Microscopy Society meeting in Lyngby Denmark offers several opportunities to meet with us and to hear about the latest HoloMonitor news.

Read more

Decision on rights issue for continued growth, establishment of sales organization and commercial break-through

The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.

Read more

PHI increase sales in fourth quarter, as well

PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter.

Read more

PHI and world-leading research institute evaluate quantitative imaging of living tumor cells

QIMR Berghofer Medical Research Institute in Brisbane and PHI have entered an evaluation agreement to explore the use of live cell time-lapse cytometry based on quantitative phase microscopy to determine the impact of hypoxic microenvironment on cellular motility and metastatic potential in solid cancers.

Read more